Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up

Background: We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once...

Full description

Bibliographic Details
Main Authors: Monika Kozieł, Michał Mazurek, Christine Teutsch, Hans-Christoph Diener, Sergio J. Dubner, Jonathan L. Halperin, Chang-Sheng Ma, Kenneth J. Rothman, Axel Brandes, Miney Paquette, Kristina Zint, Lionel Riou França, Shihai Lu, Dorothee B. Bartels, Menno V. Huisman, Gregory Y. H. Lip
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Journal of Clinical Medicine
Subjects:
atrial fibrillation
dosing frequency
GLORIA-AF
non-vitamin K antagonist oral anticoagulants
oral anticoagulants
vitamin K antagonists
Online Access:https://www.mdpi.com/2077-0383/9/6/1969

Internet

https://www.mdpi.com/2077-0383/9/6/1969

Similar Items